A study on captopril antagonized osteoporosis induced by retinoic acid in mice and it's dose-response effects

Chinese Pharmacological Bulletin

Volumn 18, Issue 5, 2002, Pages 572-575

  Chen, Fang ^a   Wu, Tie ^a   Cui, Liao ^a   Zhang, Shao Fen ^a,b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Clinical Laboratory   (China)

Author keywords

Bone hydroxyproline; Bone mineral; Captopril; Osteoporosis; Retinoic acid

Indexed keywords

CALCIUM; CAPTOPRIL; HYDROXYPROLINE; MAGNESIUM; MANGANESE; PHOSPHORUS; RETINOIC ACID; SULFONIUM DERIVATIVE; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MASS; BONE METABOLISM; BONE MINERAL; CALCIUM BONE LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; MALE; NONHUMAN; OSTEOPOROSIS; RAT;

EID: 0036815882     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Wang Y, Soper DL, Dirr MJ et al. The synthesis and human FP receptor bindingaffinity of 13, 14-dihydro prostaglandin f1alpha sulfonamides: Potential treatments for osteoporosis. Chem Pharm Bull (Tokyo), 2000;48(9):1332-7
2. 2 preferentially increase luciferase levels in bone of mice harboring a luciferase transgene controlled by elements of the pro-alpha1(I) collagen promoter. Bone, 2000;26(1):27-32
3. 1α, 1995, 23(4):229-30
4. Engelman RM, Rousou JA, Iyengar J et al. Captopril, an ACE inhibitor, for optimizing reperfusion after acute myocardial infarction. Ann Thorac Surg, 1991;52(4):918-26